PONTE
VEDRA, Fla., Sept. 23,
2024 /PRNewswire/ -- Cadrenal Therapeutics,
Inc., (Nasdaq: CVKD), a late-stage biopharmaceutical company
developing tecarfarin, a new vitamin K antagonist (VKA) designed to
be a superior and safer chronic anticoagulant for
warfarin-dependent patients with implanted cardiac devices or rare
cardiovascular conditions, announced today it will participate in a
webcast presentation and host one-on-one meetings with investors at
the Lytham Partners Fall 2024 Investor Conference, taking place
virtually on Tuesday, October 1,
2024.
Company Webcast
Cadrenal's webcast presentation will begin at 2:00 pm ET on Tuesday, October 1. Access will be
available via the conference home page at
https://lythampartners.com/fall2024/ or directly at
https://app.webinar.net/5daO3nGQlzP. The webcast will also be
available for replay following the event.
One-on-one Meetings
Cadrenal management will be participating in virtual one-on-one
meetings throughout the event. To arrange a meeting, please contact
Lytham Partners at 1x1@lythampartners.com or register for the
event at https://lythampartners.com/fall2024invreg/.
ABOUT CADRENAL THERAPEUTICS, INC.
Cadrenal
Therapeutics is a late-stage biopharmaceutical company boldly
challenging the status quo by innovating a new anticoagulant to
elevate care for underserved patients. The company is developing
the vitamin K antagonist (VKA) tecarfarin, designed to be a
superior and safer anticoagulant for individuals with implanted
cardiac devices or rare cardiovascular conditions. Cadrenal strives
to improve outcomes and reduce major events for these patients, who
lack chronic anticoagulation options besides warfarin, well-known
for its prevalent side effects and cumbersome dosing. With its
innovation, the company aims to unburden these patients and their
healthcare providers from warfarin's many challenges.
Cadrenal's late-stage drug candidate tecarfarin is a new VKA
anticoagulant that is anticipated to result in fewer adverse events
such as strokes, heart attacks, bleeds and deaths than warfarin.
Tecarfarin received an orphan drug designation for heart failure
patients with implanted left ventricular assist devices (LVADs) as
well as both orphan drug and fast-track status for end-stage kidney
disease patients with atrial fibrillation. Cadrenal is
opportunistically pursuing pivotal trials along with clinical and
commercial partnership opportunities. The company's plans also
include studying tecarfarin in patients with mechanical heart
valves experiencing anticoagulation difficulties. Visit
www.cadrenal.com.
For more information, please contact:
Cadrenal Therapeutics:
Matthew Szot, CFO
858-337-0766
press@cadrenal.com
Investors:
Lytham Partners, LLC
Robert Blum, Managing Partner
602-889-9700
CVKD@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cadrenal-therapeutics-to-participate-in-lytham-partners-fall-2024-investor-conference-302255020.html
SOURCE Cadrenal Therapeutics, Inc.
